Ophthalmic composition comprising geranylgeranylacetone

A method for reducing white turbidity of an ophthalmic composition due to storage of the composition at a low temperature,

• wherein the method comprises storing the composition at the low temperature for at least three days, and
• the ophthalmic composition comprises geranylgeranylacetone selected from the group consisting of:
• (a) a mixture of at least two geometric isomers of geranylgeranylacetone, wherein the mixture contains at least 80% by weight or more of (5E,9E,13E)-geranylgeranylacetone relative to the total weight of the mixture, and
• (b) (5E,9E,13E)-geranylgeranylacetone,
• thereby reducing the white turbidity of the ophthalmic composition due to storage of the composition at the low temperature.

A method for reducing white turbidity of an ophthalmic composition due to storage of the composition,

• wherein the method comprises storing the composition for at least three days, and
• the ophthalmic composition comprises geranylgeranylacetone selected from the group consisting of:
• (a) a mixture of at least two geometric isomers of geranylgeranylacetone, wherein the mixture contains at least 80% by weight or more of (5E,9E,13E)-geranylgeranylacetone relative to the total weight of the mixture, and
• (b) (5E,9E,13E)-geranylgeranylacetone,
• thereby reducing the white turbidity of the ophthalmic composition due to storage of the composition.

A method for providing an activity of suppressing eye irritancy to an ophthalmic composition,

• wherein the method comprises adding to the composition a geranylgeranylacetone selected from the group consisting of:
• (a) a mixture of at least two geometric isomers of geranylgeranylacetone, wherein the mixture contains at least 80% by weight or more of (5E,9E,13E)-geranylgeranylacetone relative to the total weight of the mixture, and
• (b) (5E,9E,13E)-geranylgeranylacetone,
• thereby providing the activity of suppressing eye irritancy to the ophthalmic composition.

A method for suppressing eye irritancy of an ophthalmic composition comprising geranylgeranylacetone,

• wherein the method comprises contacting an eye of a human with the composition, and the geranylgeranylacetone is selected from the group consisting of:
• (a) a mixture of at least two geometric isomers of geranylgeranylacetone, wherein the mixture contains at least 80% by weight or more of (5E,9E,13E)-geranylgeranylacetone relative to the total weight of the mixture, and
• (b) (5E,9E,13E)-geranylgeranylacetone,
• thereby suppressing the eye irritancy of the ophthalmic composition.